Organization | Vaccitech Limited

Vaccitech Limited Report issue

For profit Phase 2

Founded: Oxford United Kingdom (2016)

Organization Overview

First Clinical Trial

2017

NCT03277456

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Vaccitech Limited | Vaccitech (UK) Limited

Active Ingredients

Drugs in Phase 2 Trials (14)

chadox1-hbv (3 trials)

chadox1-hpv (1 trial)

chadox1-magea3-nyeso (1 trial)

chadox1-mva 5t4 (1 trial)

chadox1-pcaq (1 trial)

inactivated influenza vaccine (2 trials)

matrix m1 (4 trials)

mva-hbv (2 trials)

mva-hpv (1 trial)

mva-magea3 (1 trial)

mva-np (4 trials)

mva-pcaq (1 trial)

nivolumab (opdivo) (3 trials)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hepatitis B (Phase 1)

Influenza, Human (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 11
# of Trial APIs: 14